Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction
| Autor: | R.J. Lennane, F. Van de Werf, G.A.vande Kley, P.L. Michel, R. Von Essen, Ronald W. Brower, Desire Collen, Charbonnier B, Walter Bleifeld, D.P. de Bono, Jacobus Lubsen, Joachim Schofer, A Vahanian, Detlef G. Mathey, A.J. Dunning, Vanhaecke J, Ph. Raynaud, M. Verstraete |
|---|---|
| Rok vydání: | 1985 |
| Předmět: |
Adult
Male Randomization medicine.medical_treatment Myocardial Infarction Placebo Coronary Angiography law.invention Fibrin Fibrinogen Degradation Products Random Allocation Randomized controlled trial Double-Blind Method law Angioplasty medicine Humans Myocardial infarction Coronary Artery Bypass Aged Chemotherapy Clinical Trials as Topic business.industry Fibrinogen General Medicine Middle Aged medicine.disease Clinical trial Anesthesia Tissue Plasminogen Activator Female business Plasminogen activator Angioplasty Balloon |
| Zdroj: | Lancet (London, England). 2(8462) |
| ISSN: | 0140-6736 |
| Popis: | In a double-blind randomised trial 129 patients with first myocardial infarction of less than 6 h duration were allocated to treatment with human recombinant tissue-type plasminogen activator (rt-PA) given intravenously over 90 min, or to placebo infusion. Coronary angiography at the end of this infusion showed that the infarct-related vessel was patent in 61% of 62 assessable coronary angiograms in the rt-PA-treated group compared with 21% in the control group. Treatment with rt-PA was not accompanied by any major complications. In the rt-PA group the circulating fibrinogen level at the end of the catheterisation was 52 +/- 29% (mean +/- SD) of the starting value. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|